FOLH1 and prostate carcinoma: The pool of studies that analyzed the power of 68Ga-PSMA PET in restaging recurrent prostate cancer resulted in a sensitivity of 0.76 (0.74 to 0.78), with heterogeneity of 96.7% (Figure-7).